Summary
Long gone are the days when a drug successfully completing Phase III trials was virtually assured of launch.
The results of late-stage clinical trials are scrutinised as never before, and even products that surmount safety and efficacy requirements must overcome increasingly challenging pharmacoeconomic and medical outcome hurdles.
The high cost of new cancer therapies has made them targets for critical analysis. The rewards may be great for patients and companies alike, but successfully bringing a new product to market is a complex, difficult-to-predict business.
Tracking and evaluating these new products through their late-stage development is essential and that is why both industry and the investment community will value this comprehensive new service from one of the world's leading providers of oncology business data.
Please Note: The publisher will not fulfil orders to a personal email address, you must supply a work or business address.
|
